The board of directors of BioNanomatrix has tapped Edward Erickson to take over as CEO and president of the company. Erickson, who was previously executive chairman of the board, takes over the post from Michael Boyce-Jacino. Tracey Warren, general partner at Battelle Ventures, will succeed Erickson as chairperson. Erickson has served as a director at BioTrove and at Barrier Therapeutics.
Lynn L'Archeveque has recently joined Schott as the US east coast sales manager for its Nexterion microarray products.
Prior to joining Schott, L'Archeveque worked in business development at NextBio and Biocompare.
Sequenom has appointed Kenneth Buechler and David Pendarvis to its board of directors. Buechler previously was president, chief scientific officer, and co-founder of Biosite. Pendarvis is senior vice president of organizational development, global general counsel, and secretary of ResMed.
Robert Langer has been named to Millipore's board of directors, where he will take the place of exiting director Daniel Bellus. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology. He also serves on the board of MIT's McGovern Institute and Whitehead Institute.
Regis Technologies has named four new members to its scientific staff, all former employees at DeCode Genetics. The appointments include Nelson Zhao, Igor Likhotvorik, Sied Zegar, and Dragan Ristic, all of which are from DeCode's development and production staff.